The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps. The paraloid-B-48 material (10.59 wt %) is added to ethyl acetate (31.77 wt %) slowly under constant agitation. The mixture comprising paraloid-B-48 material and ethyl acetate is agitated till no lumps are present. The butyl acetate (8.47 wt %), TAXIB Plasticizer (0.70 wt %), propylene glycol monomethyl ether (PM) acetate (19.77 wt %), ethyl acetate (28.24 wt %), Chemia #46210 Lavandin (0.42 wt %) and dimethyl ether to the mixture comprising paraloid-B-48 material and ethyl acetate are added to the mixture comprising paraloid B-48 material and ethyl acetate to obtain a composition. The composition is blended at a predetermined speed to uniformly mix the components.

The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps. The paraloid-B-48 material (10.59 wt %) is added to ethyl acetate (31.77 wt %) slowly under constant agitation. The mixture comprising paraloid-B-48 material and ethyl acetate is agitated till no lumps are present. The butyl acetate (8.47 wt %), TAXIB Plasticizer (0.70 wt %), propylene glycol monomethyl ether (PM) acetate (19.77 wt %), ethyl acetate (28.24 wt %), Chemia #46210 Lavandin (0.42 wt %) and dimethyl ether to the mixture comprising paraloid-B-48 material and ethyl acetate are added to the mixture comprising paraloid B-48 material and ethyl acetate to obtain a composition. The composition is blended at a predetermined speed to uniformly mix the components.

A method of treating a periodontal pocket, comprising a step of administering one or more biodegradable compounds in a suitable carrier into the periodontal pocket, wherein the compound induces partial or total filling of the periodontal pocket for a period of time. Preferably, the biodegradable compound is Poly-L-lactic acid.

A method of treating a periodontal pocket, comprising a step of administering one or more biodegradable compounds in a suitable carrier into the periodontal pocket, wherein the compound induces partial or total filling of the periodontal pocket for a period of time. Preferably, the biodegradable compound is Poly-L-lactic acid.

Compounds of the formulae ##STR00001##
and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula ##STR00002## wherein G.sub.1 is hydrogen; C.sub.1-C.sub.22alkyl; C.sub.1-C.sub.22alkylthio; C.sub.2-C.sub.22alkylthioalkyl; C.sub.5-C.sub.7cycloalkyl; phenyl; C.sub.7-C.sub.9-phenylalkyl; or SO.sub.3M; G.sub.2 is C.sub.1-C.sub.22alkyl; C.sub.5-C.sub.7cycloalkyl; phenyl; or C.sub.7-C.sub.9-phenylalkyl; E is oxyl or hydroxyl; V is O; or NH; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G.sub.3 are as defined in claim 1; G.sub.4 and G.sub.5 are each independently of the other hydrogen; or C.sub.1-C.sub.22alkyl; exhibit marked antiinflammatory action.

The present disclosure relates to HIF-2 inhibitors and methods of making and using them for treating iron overload disorders. Certain compounds were potent in HIF-2 scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and reduced liver iron accumulation and serum iron parameters in both prophylactic and treatment mouse models.

A method for treating a cancer includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Monobenzone or a pharmaceutical acceptable salt thereof. The cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, and skin cancer. The pleural-related cancer is lung cancer. The abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer. The endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer. The gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.